nach oben

Diabetologia

Erschienen in:

01.07.2010 | Article

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients

verfasst von: G. Targher, L. Bertolini, M. Chonchol, S. Rodella, G. Zoppini, G. Lippi, L. Zenari, E. Bonora

Erschienen in: Diabetologia | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased prevalence of chronic kidney disease (CKD) and retinopathy in patients with type 2 diabetes. Information on this issue is lacking for type 1 diabetes. We evaluated whether NAFLD is associated with increased prevalence of retinopathy and CKD in type 1 diabetic patients.

Methods

All type 1 diabetic patients (n = 202) who regularly attended our diabetes clinic and did not have any clinical evidence of cirrhosis or other secondary causes of chronic liver disease were studied. Main study measures were detection of NAFLD (by patient history and liver ultrasound), diabetic retinopathy (diagnosed by ophthalmoscopy) and CKD (defined as abnormal albuminuria or estimated GFR of ≤60 ml min⁻¹ 1.73 m⁻²).

Results

The age- and sex-adjusted prevalence of diabetic retinopathy (53.2 vs 19.8%) and CKD (37.8 vs 9.9%) was markedly higher in patients with NAFLD than in those without (p < 0.0001). In multivariate logistic regression analysis, NAFLD was associated with prevalent retinopathy (adjusted OR 3.31, 95% CI 1.4–7.6, p = 0.005) or CKD (adjusted OR 3.90, 95% CI 1.5–10.1, p = 0.005). These associations were independent of age, sex, diabetes duration, HbA_1c, medication use and presence of the metabolic syndrome.

Conclusions/interpretation

Our findings suggest that ultrasound-diagnosed NAFLD is associated, independently of several confounding factors, with a higher prevalence of CKD and retinopathy in type 1 diabetic individuals.

Adams LA, Lindor KD (2007) Nonalcoholic fatty liver disease. Ann Epidemiol 17:863–869CrossRefPubMed

de Alwis NMW, Day CP (2008) Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol 48(Suppl 1):S104–S112PubMed

Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRefPubMed

Targher G, Marra F, Marchesini (2008) Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51:1947–1953CrossRefPubMed

Misra VL, Khashab M, Chalasani N (2009) Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep 11:50–55CrossRefPubMed

Targher G, Bertolini L, Rodella S et al (2008) Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51:444–450CrossRefPubMed

Mohamed Q, Gillies M, Wong TY (2007) Management of diabetic retinopathy: a systematic review. JAMA 298:902–916CrossRefPubMed

Rossing P (2006) Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 49:11–19CrossRefPubMed

Targher G, Bertolini L, Padovani R et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218CrossRefPubMed

10.

Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483CrossRefPubMed

11.

American Diabetes Association (2010) Standards of medical care in diabetes—2010. Diabetes Care 33(Suppl 1):S11–S61CrossRef

12.

Sattar N, Gaw A, Scherbakova O et al (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414–419CrossRefPubMed

13.

Girman CJ, Rhodes T, Mercuri M, 4S Group and the AFCAPS/TexCAPS Research Group et al (2004) The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93:136–141CrossRefPubMed

14.

Wilkinson CP, Ferris FL, Klein RE, Global Diabetic Retinopathy Project Group et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682CrossRefPubMed

15.

Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD (1991) Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43:26–31CrossRefPubMed

16.

Saadeh S, Younossi ZM, Remer EM et al (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745–750CrossRefPubMed

17.

Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD (2008) Non-invasive means of measuring hepatic fat content. World J Gastroenterol 14:3476–3483CrossRefPubMed

18.

Targher G, Bertolini L, Poli F et al (2005) Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541–3546CrossRefPubMed

19.

Targher G, Bertolini L, Rodella S et al (2007) Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30:2119–2121CrossRefPubMed

20.

Thorn LM, Forsblom C, Fagerudd J, FinnDiane Study Group et al (2005) Metabolic syndrome in type 1 diabetes. Association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024CrossRefPubMed

21.

Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate. The Pittsburgh Epidemiology of Diabetes Complications Study Experience. Diabetes Care 30:1248–1254CrossRefPubMed

22.

Kilpatrick ES, Rigby AS, Atkin SL (2007) Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 30:707–712CrossRefPubMed

23.

Prati D, Taioli E, Zanella A et al (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1–10PubMed

24.

Mofrad P, Contos MJ, Haque M et al (2003) Clinical and histological spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286–1292CrossRefPubMed

25.

Ratziu V, Imbert-Bismut F, Messous D, Poynard T (2004) The elusiveness of “normal” ALT in fatty liver. Hepatology 39:1172CrossRefPubMed

26.

Targher G, Chonchol M, Bertolini L et al (2008) Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 19:1564–1570CrossRefPubMed

27.

Targher G, Kendrick J, Smits G, Chonchol M (2010) Relationship between elevated serum gamma-glutamyltransferase concentrations and chronic kidney disease in the United States population. Findings from the National Health and Nutrition Examination Survey 2001–2006. Nutr Metab Cardiovasc Dis. doi:10.1016/j.numecd.2009.05.012 PubMed

28.

Targher G, Bosworth C, Kendrick J, Smits G, Lippi G, Chonchol M (2009) Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001–2006. Clin Chem Lab Med 47:1055–1062CrossRefPubMed

29.

Ryu S, Chang Y, Kim DI, Kim WS, Suh BS (2007) Gamma-glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 53:71–77CrossRefPubMed

30.

Lee DH, Jacobs DR, Gross M, Steffes M (2005) Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension and diabetes: the Coronary Artery Risk development in Young Adults (CARDIA) study. Clin Chem 51:1185–1191CrossRefPubMed

31.

Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M (2009) Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 35:277–287CrossRefPubMed

32.

Edens MA, Kuipers F, Stolk RP (2009) Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 10:412–419CrossRefPubMed

33.

Yoneda M, Mawatari H, Fujita K et al (2007) High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 42:573–582CrossRefPubMed

34.

Thuy S, Ladurner R, Volynets V et al (2008) Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 138:1452–1455PubMed

35.

Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE (2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103:1372–1379CrossRefPubMed

Titel: Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients
verfasst von: G. Targher
L. Bertolini
M. Chonchol
S. Rodella
G. Zoppini
G. Lippi
L. Zenari
E. Bonora
Publikationsdatum: 01.07.2010
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 7/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-010-1720-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2010

TRIB3 R84 variant affects glucose homeostasis by altering the interplay between insulin sensitivity and secretion

IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes

Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study

Variants in ACAD10 are associated with type 2 diabetes, insulin resistance and lipid oxidation in Pima Indians

Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study

Metformin suppresses hepatic gluconeogenesis and lowers fasting blood glucose levels through reactive nitrogen species in mice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin